A Pilot Study of a DNAJB1-PRKACA fusion kinase vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar carcinoma (FLC)

Timeframe: 2019-2022 Goal: Assess potential to induce immune response with a FLC therapeutic vaccine Principal Investigator: Mark Yarchoan, MD, Associate Professor, Oncology/Division of GI Malignancies, Sidney Kimmel Comprehensive Cancer Center FLC is a rare and often lethal form of liver cancer for which there is no standard treatment option beyond surgery. Immune checkpoint inhibitors are …

Read more

Opening of FLC peptide vaccine clinical trial

Timeframe: 2020 – 2022 Goal: Assess potential to induce immune response with a FLC therapeutic vaccine Principal Investigator: Mark Yarchoan, MD, Associate Professor, Oncology/Division of GI Malignancies, Sidney Kimmel Comprehensive Cancer Center This clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns …

Read more

A phase I/II study of nivolumab plus 5-fluorouracil plus interferon-α2b for unresectable fibrolamellar hepatocellular carcinoma

Timeframe: 2021 – 2022 Goal: Assess the potential of the combination of nivolumab, fluorouracil, and interferon alpha-2b as a treatment option for unresectable disease Principal Investigators: Sunyoung Lee, MD and Ahmed Kaseb, MD, University of Texas M.D. Anderson Cancer Center This phase I/II trial studies the side effects and how well the combination of nivolumab, …

Read more

Everolimus clinical trial

Timeframe: 2012 – 2014 Goal: Assess potential of treatment options for FLC Principal Investigator: Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center FCF funded the first clinical trial of drugs aimed specifically at fibrolamellar liver cancer.  The trial was also conducted at other consortium members, including the University of California San Francisco, Johns Hopkins, and Dana …

Read more